Taipale and collaborators, as a part of the Finnish nationwide register of patients in hospital treatment, carried out a case–control study investigating the effect of prolactin-raising antipsychotics on the risk of breast cancer in schizophrenia populations [53]. This evidence concerns the gene PRL and breast cancer.